A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

Demos, a medical doctor who was the Vice President of Drug Safety and Pharmacovigilance and member of the drug label team at ...

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the company's products ...

Insiders have been trading these 5 stocks: (($ACAD)), (($EPR)), (($APLE)), (($KTOS)) and (($TSE:EFR)). Here is a breakdown of ...

The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13. March 10 marked its worst single-day decline in almost two years, plunging 4% as investor ...

George Demos, former vice president of drug safety and pharmacovigilance at Acadia Pharmaceuticals Inc., is the latest biopharma executive to plead guilty to insider trading charges. BioWorld ...

ACADIA Pharmaceuticals Inc. continues to navigate a complex market environment, balancing the growth of its established products with the development of its pipeline. Trading at an EV/EBITDA ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They ...